Partamian L G, Kass M A, Gordon M
Am J Ophthalmol. 1983 Feb;95(2):229-32. doi: 10.1016/0002-9394(83)90018-1.
We conducted a randomized, double-masked, dose-response study of the ocular hypotensive effect of the beta-adrenergic blocker, levobunolol. A single drop of placebo or levobunolol (at concentrations of 0.03%, 0.3%, 0.6%, 1%, and 2%) was administered to one eye of each of 48 patients with ocular hypertension. The 0.3% and 0.6% concentrations decreased intraocular pressure significantly from baseline levels compared to placebo at one, two, and four hours after treatment. The 1% and 2% concentrations decreased intraocular pressure significantly from baseline compared to placebo at one, two, four, six, eight, and 12 hours after administration. No objective or subjective side effects were noted, and no substantial changes in visual acuity, pupil diameter, pulse rate, or blood pressure were recorded during the study. These results appear to justify long-term studies of levobunolol for the treatment of increased intraocular pressure.
我们对β-肾上腺素能阻滞剂左布诺洛尔的降眼压作用进行了一项随机、双盲、剂量反应研究。对48例高眼压患者的每只眼睛滴入一滴安慰剂或左布诺洛尔（浓度分别为0.03%、0.3%、0.6%、1%和2%）。与安慰剂相比，0.3%和0.6%浓度的左布诺洛尔在治疗后1小时、2小时和4小时使眼压较基线水平显著降低。1%和2%浓度的左布诺洛尔在给药后1小时、2小时、4小时、6小时、8小时和12小时使眼压较基线水平显著降低。未观察到客观或主观副作用，研究期间未记录到视力、瞳孔直径、脉搏率或血压的实质性变化。这些结果似乎为左布诺洛尔治疗眼压升高的长期研究提供了依据。
